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Abstract
There is increasing evidence that the physical environment is a critical mediator of tumor
behavior. Hepatocellular carcinoma (HCC) develops within an altered biomechanical environment
and increasing matrix stiffness is a strong predictor of HCC development. The aim of this study
was to establish whether changes in matrix stiffness, which are characteristic of inflammation and
fibrosis, regulate HCC cell proliferation and chemotherapeutic response. Using an in vitro system
of “mechanically-tunable” matrix-coated polyacrylamide gels, matrix stiffness was modeled
across a pathophysiologically-relevant range, corresponding to values encountered in normal and
fibrotic livers.
Results—Increasing matrix stiffness was found to promote HCC cell proliferation. The
proliferative index (assessed by Ki67 staining) of Huh7 and HepG2 cells was 2.7-fold and 12.2-
fold higher, respectively, when the cells were cultured on stiff (12kPa) versus soft (1kPa) supports.
This was associated with stiffness-dependent regulation of basal and HGF-stimulated mitogenic
signaling through extracellular regulated kinase (ERK), protein kinase B (PKB/Akt) and signal
transducer and activator of transcription 3 (STAT3). β1-integrin and focal adhesion kinase (FAK)
were found to modulate stiffness-dependent HCC cell proliferation. Following treatment with
cisplatin, we observed reduced apoptosis in HCC cells cultured on a stiff versus soft
(physiological) supports. Interestingly, however, surviving cells from soft supports had
significantly higher clonogenic capacity than surviving cells from a stiff microenvironment. This
was associated with enhanced expression of cancer stem cell markers, including CD44, CD133, c-
kit, CXCR4, octamer-4 (OCT4) and NANOG.
Conclusion—Increasing matrix stiffness promotes proliferation and chemotherapeutic
resistance, whereas a soft environment induces reversible cellular dormancy and stem cell
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characteristics in HCC. This has implications for both the treatment of primary HCC and the
prevention of tumor outgrowth from disseminated tumor cells.
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Introduction
Hepatocellular carcinoma (HCC) is the third-most common cause of cancer related mortality
world-wide (1). The majority (80%) of HCCs develop in the context of advanced liver
fibrosis or cirrhosis and liver cirrhosis is the single most important risk factor for HCC
development (2). Liver fibrosis is defined by stereotypical changes in both the biochemical
and physical properties of the cellular microenvironment. However, the role of mechanical
factors in modulating the growth and progression of HCC remain poorly defined. Recent
studies involving ultrasound elastography (FibroScan) demonstrate that liver stiffness
measurements are a strong predictor of HCC development (3). Furthermore, once
established, tumor development is associated with further increases in matrix stiffness to
values greater than those of the surrounding hepatic parenchyma (4). It is therefore evident
that HCC develops in a niche with mechanical properties distinct from those encountered in
the normal liver.
Cancer development and progression is dependent upon both intrinsic genetic abnormalities
and external structural determinants (5). Matrix stiffness has recently been directly
implicated in aiding tumor development. Increases in matrix stiffness that enhance cell
contractility have been found to be sufficient to enhance the transformation of mammary
epithelial cells (6). Conversely, a reduction in tissue stiffness by inhibition of collagen cross-
linking impedes malignant growth and tumor development in a murine model of breast
cancer (7). Cellular stiffness-sensing relies upon intracellular tension, which is determined
by a dynamic equilibrium between forces generated by a contractile cytoskeleton and the
elastic resistance (stiffness) provided by the ECM. In this context, cancer progression (tumor
growth, invasion and dissemination) is accompanied by changes in both the mechanical
properties of the cancer cell niche and changes in cellular contractility (modified by genetic
and epigenetic factors) that regulate tumor cell behavior.
HCC continues to have a poor prognosis (median survival less than 12 months), reflecting
its late presentation and lack of effective therapies (8,9). The effectiveness of both hepatic
resection and liver transplantation for HCC is limited by tumor recurrence, which can occur
months or years following resection of a primary tumor (10). Furthermore, systemic
chemotherapy has proved ineffective both for the treatment of advanced HCC and in an
adjuvant/ neoadjuvant setting for the eradication of disseminated (dormant) tumor cells, the
progenitors of clinical metastases. The mechanisms underlying chemotherapy resistance in
HCC have not been fully elucidated. Although it has previously been demonstrated that the
composition of the matrix can enhance chemotherapy resistance in a range of epithelial
cancers (11,12), the role of matrix stiffness has not been specifically addressed for HCC or
other epithelial cancers.
Here we demonstrate that mechanical factors regulate both the proliferation and
chemotherapeutic response of HCC cells. In addition, we show that both tumor cell
differentiation and cancer stem cell characteristics are influenced by the mechanical
properties (stiffness) of the cancer cell niche.
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Materials and Methods
Cell Culture and Microscopy
Human HCC cell lines Huh7 and HepG2 (kindly provided by S. Wigmore, Edinburgh, UK)
were cultured in Dulbecco’s Modified Eagle Medium (Gibco, Paisley, UK) supplemented
with 10% fetal calf serum, penicillin/ streptomycin and L-glutamine. For all experiments
cells were plated at semi-confluent density in 1% fetal calf serum. Chemical reagents were
purchased from Sigma (Poole, UK) unless otherwise stated. Transforming growth factor-
beta (TGFβ) and hepatocyte growth factor (HGF) (Peprotech, London, UK) were used at
concentrations of 5ng/ml and 10ng/ml, respectively. Anti-β1-integrin, clone 6S6 (Millipore,
Watford, UK) and control IgG1 immunoglobulin (AbD Serotec, Oxford, UK) were used for
cell culture experiments at 50µg/ml. Echistatin (Tocris, Bristol, UK) was used in cell culture
experiments at 100nM concentration. The chemical FAK inhibitor, PF573228 (Tocris,
Bristol, UK) was solubilized in dimethyl-sulfoxide (DMSO) and used for cell culture
experiments at a concentration of 1–5µM. A detailed description of microscopy and
morphological analysis can be found in Supplementary Methods online.
Preparation of Polyacrylamide Gel Supports
Polyacrylamide (PA) gels of variable stiffness were prepared on glass coverslips using
modifications (13) to the method initially described by Pelham and Wang (14). A detailed
description can be found in the Supplementary Methods online.
Immunofluorescence Staining
Cells were fixed in 4% paraformaldehyde in PBS and permeabilized with 0.2% Triton-
X-100 in PBS. Slides were stained with anti-Ki67 (Novocastra, Newcastle, UK) and anti-
vinculin (Sigma, Poole, UK); corresponding Alexa Fluor-555 secondary antibodies were
used for detection (Invitrogen, Paisley, UK). Actin stress fibers were stained with Alexa-488
Phalloidin (Invitrogen, Paisley, UK). Nuclear DNA was counterstained with 4’, 6’-
diamidino-2-phenyl-indole dihydrochloride (DAPI) (Dako, Ely, UK). Cellular proliferative
index (Ki67 positive cells/total cells) was calculated by direct cell counting from 15
randomly selected high magnification photomicrographs from Ki67-stained slides (n=3).
Western Blot
A detailed description of western blotting and a complete list of antibodies are provided in
the supplementary methods online.
Immunohistochemistry
Human HCC specimens were obtained from archived tissue held by Tayside Tissue Bank
and the Department of Pathology, University Medical Center Hamburg-Eppendorf with
appropriate ethical approval (UK-LREC: TR000216). Immunohistochemistry was
performed as previously described (15). The primary antibodies and antigen retrieval
regimes used were anti-pFAK (pY397) (Invitrogen, Paisley, UK/ Microwave pH9) and anti-
β1-integrin (Abcam, Cambridge, UK/ Microwave pH9). Negative controls with isotype
immunoglobulins (Santa Cruz, Heidelberg, Germany) and species-specific serum alone
showed no specific staining.
Clonogenic Assay
Cells were plated at semi-confluent density onto PA gels. After 48h cells either received
cisplatin (HepG2 10µM/ Huh7 20µM) or 5-fluorouracil (5FU/ 25µM) or were left untreated
in plating medium. After 24h the medium was changed to normal culture medium and the
cells were incubated further for 48h, for a total of 5 days of culture. Cells were then
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retrieved by trypsinization, counted and plated at clonal density (10,000 cells/well) into 12-
well plates in normal culture medium. Cells were fixed at between 5–10 days in 4%
paraformaldehyde and stained with 0.5% crystal violet solution. Colonies were visualized
with a VersaDoc system and analyzed with Quantify-One (BioRad, Hercules, USA).
Flow-Cytometric Analysis
Cells were harvested by trypsinization and single cell suspension generated by passing cells
through a 40µm cell strainer. Cells were stained with the following antibodies: CD44-PE,
CD117-PE (c-kit), CD133-PE, CD184-PE (CXCR-4) and corresponding PE-labelled isotype
controls (E-Bioscience, Hatfield, UK). After staining, cells were washed, post-fixed in 1%
paraformaldehyde and analyzed on a FACScan (BD Biosciences, Franklin Lakes, USA).
Data analysis was performed using FlowJo software (Tree-Star Inc, Ashland, USA).
cDNA Synthesis and Real-Time PCR
Relative mRNA expression for genes of interest was determined by Real-Time PCR using
an Applied Biosystems 7700 Sequence Detection System. Primer sequences for the genes of
interest and the 18S housekeeping gene were purchased from Applied Biosystems
(Warrington, UK).
Statistics
Data are expressed as mean +/− standard error of the mean (SEM) of at least three
independent experiments unless stated otherwise. Comparisons between groups were
performed using a two-tailed student t-test.
Results
Increasing Matrix Stiffness is Associated with a Mesenchymal Shift in HCC Cells
The response of HCC cells to alterations in matrix stiffness was investigated using a system
of mechanically-tunable ligand-coated PA gels (13,14). In this system, matrix stiffness is
altered by modulating the bis-acrylamide crosslink density of thin PA gels without altering
the surface composition or density of ligands to which the cells are exposed (13). Matrix
stiffness (expressed as shear modulus, G’) was modeled across a range of
pathophysiologically-relevant stiffness values (1–12kPa) corresponding to values
encountered in normal and fibrotic livers (16). The PA gels used in this study were coated
with collagen-I, representing the predominant ECM protein encountered in the fibrotic liver.
For both Huh7 and HepG2 cells we observed a consistent morphological response to
changes in support stiffness. HCC cells on soft (1kPa) supports were small and rounded in
contrast to the well-spread and flattened cells seen on stiff (12kPa) supports (Figure 1).
Differences in cellular spreading as a function of support stiffness develop rapidly (within 1
hour) and are maximal at 24 hours (Figure S1). Confocal microscopy showed that increasing
matrix stiffness was associated with the development of prominent actin stress fibers and
mature (vinculin-positive) focal adhesions (Figure 2). These features were absent in cells
cultured on soft supports. The presence of stress fibers is linked to acquisition of
mesenchymal properties (mesenchymal-shift) and de-differentiation in epithelial cells. In
accordance with this we demonstrated upregulation of the mesenchymal markers N-cadherin
(Huh7/HepG2) and vimentin (shown for Huh7; vimentin is not expressed in HepG2 cells
under either condition) in HCC cells cultured on stiff supports (Figure 3A). There was no
change in the expression of the epithelial marker E-cadherin. HepG2 and Huh7 cells
cultured on soft supports expressed higher levels of albumin, hepatocyte nuclear factor-4α
(HNF4α), α1-antitrypsin and alpha-fetoprotein (AFP) than cells cultured on stiff supports
(Figure 3B). This suggests that a soft environment promotes a differentiated hepatocyte
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phenotype, whereas increasing support stiffness is associated with cellular de-differentiation
towards a mesenchymal phenotype.
TGFβ is a potent inducer of mesenchymal changes in both primary and transformed
epithelial cells. We therefore investigated whether support stiffness regulated TGFβ-induced
Smad signaling activity in HCC cells. The Huh7 cell line demonstrated increased basal
activity of the TGFβ signaling pathway (as indicated by increased Smad3 phosphorylation)
in cells cultured on stiff supports (Figure 3C/D). In addition, upon stimulation with TGFβ
there was enhanced Smad2 and Smad3 phosphorylation in cells from stiff supports.
Increasing Matrix Stiffness Promotes HCC Proliferation
In both HCC cell lines, matrix stiffness regulated HCC cell proliferation (Figure 4A). The
proliferative indices of Huh7 and HepG2 cells (assessed by nuclear localization of Ki67)
were 2.7-fold (p<0.001) and 12.2-fold (p<0.001) higher, respectively, when the cells were
cultured on stiff (12kPa) versus soft (1kPa) supports. Maximal proliferative index was seen
when cells were cultured on collagen-I-coated glass, which has a shear modulus several
orders of magnitude higher than any physiological matrix. Both MTT assay (Figure S2) and
direct cell counting (data not shown) confirmed an increase in total cell number with
increasing support stiffness. A similar trend for cellular proliferation was observed in
primary mouse hepatocytes (Figure S3). Matrix stiffness had a corresponding effect on the
expression of cell cycle regulators of G1 progression (Figure 4B/C). We observed a strong
reduction in the expression of cyclin-D1 and cyclin-D3 in cells cultured on soft supports.
There was no evidence of upregulation of the cyclin-dependent kinase inhibitors p21cip or
p27kip on soft gels and indeed a moderate down-regulation of p27kip was observed on soft
gels. Induction of terminal senescence on soft supports was excluded by showing that upon
transfer to a stiff matrix, cells resumed proliferation to levels comparable to cells coming
from a stiff matrix (Figure S4A). Furthermore, cells on both soft and stiff supports showed
no evidence of beta-galactosidase accumulation (data not shown). In each cell line,
differences in cellular proliferation as a function of stiffness were evident across a wide
range of plating densities (Figure S5).
In order to exclude a specific effect related to collagen-I, we investigated the effect of
different ECM coatings on HCC cell proliferation on PA gels (Figure 4D). While minor
differences were observed with respect to cellular morphology and spreading (Figure S6)
when cells were plated on collagen-I, collagen-IV, laminin and fibronectin-coated gels, the
biochemical composition of the surface coating did not significantly alter the stiffness-
dependent regulation of cell proliferation. In other words, the physical rather than the
biochemical properties of the PA gels exerted the predominant effect on HCC cell
proliferation.
Matrix Stiffness Modulates Basal and HGF-induced Signaling Responses
Using immunoblotting with phosphorylation-specific antibodies we analyzed stiffness-
dependent differences in the activity of critical mitogenic signaling pathways. Growth on
stiff (12kPa) versus soft (1kPa) supports was associated with enhanced focal adhesion
kinase (FAK), extracellular-regulated-kinase (ERK), protein kinase B (PKB/Akt) (Huh7
cells only) and signal transducer and activator of transcription-3 (STAT3) phosphorylation
(Figure 5A). Substrate stiffness significantly modulated growth factor-induced mitogenic
signaling in response to HGF. Upon stimulating cells plated on both soft and stiff PA gels
with HGF we observed an increase in the magnitude of ERK, PKB/Akt and STAT3
activation in cells cultured on stiff gels (Figures 5C/S7). Substrate stiffness also modulated
cyclin-D1 expression in response to HGF stimulation. Following HGF stimulation in HepG2
and Huh7 cells, there was upregulation of cyclin-D1 expression in cells cultured on both soft
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and stiff supports (Figure 5B). Importantly, the magnitude of cyclin-D1 induction following
HGF stimulation was substantially higher in cells cultured on stiff supports.
β1-Integrin and phospho-FAK are expressed in human HCC tumors and regulate the
stiffness-dependent proliferation of human HCC cells in vitro
Integrins and integrin-associated focal adhesions are known to be important mediators of
mechanotransduction. We therefore used immunohistochemistry to investigate the
prevalence of β1-integrin and phospho-FAKTyr397 expression in HCC tissue from an
unselected cohort of 15 HCC specimens obtained at the time of tumor resection or biopsy
(Figure 6A). β1-integrin was expressed in tumor tissue in 15/15 HCC specimens tested. In
addition we found upregulation of FAK expression in tumor tissue relative to the
surrounding parenchyma in 8/15 (53%) HCC specimens tested. These results are consistent
with published histological studies (17, 18). We subsequently investigated the effect of the
β1-integrin inhibition on HCC cell proliferation in vitro using a function blocking anti-β1-
integrin antibody (6S6) and the dysintegrin echistatin (Figure 6C). Anti-β1-integrin antibody
and echistatin promoted cellular rounding in both the Huh7 and HepG2 cells cultured on
collagen-I-coated 12kPa (stiff) supports. Huh7 cell proliferation was reduced by treatment
with both 6S6 antibody (38% reduction, p<0.05) and echistatin (29% reduction, p=0.07)
relative to relevant controls. Similarly, in HepG2 cells, cell proliferation was reduced by
treatment with both 6S6 antibody (92% reduction, p<0.001) and echistatin (21% reduction,
p<0.01). The effect of FAK activation on HCC cell proliferation was investigated in
experiments with the small molecular FAK inhibitor PF573228 (Figure 6B/C). Treatment
with PF573228 (5µM) was associated with a reduction in the proliferation of both Huh7
(42% reduction, p<0.01) and HepG2 cells (45% reduction, p<0.001) cultured on collagen-I-
coated 12kPa polyacrylamide gels. Furthermore, inhibition of β1-integrin or FAK
expression in HepG2 cells with siRNA resulted in a significant reduction in cellular
proliferation relative to control siRNA transfection (Figure S8). A similar trend in respect to
cellular proliferation was observed following siRNA-dependent inhibition of β1-integrin or
FAK expression in Huh7 cells, although in this case the reduction was not statistically
significant.
Matrix Stiffness Modulates HCC Apoptosis and Clone-forming Capability Following
Chemotherapy
HCC is resistant to treatment with conventional chemotherapeutic agents. We therefore
investigated whether the stiffness of the cancer cell niche regulates the susceptibility of HCC
cells to chemotherapy-induced apoptosis. In both cell lines, there was decreased apoptosis –
as indicated by reduced Poly-ADP-ribose polymerase (PARP) cleavage – in cells cultured
on stiff supports (Figure 7A). There was a non-significant trend towards increased numbers
of surviving cells on stiff supports (data not shown). We also performed a series of
clonogenic assays to investigate whether changes in matrix stiffness modulate the survival
and behavior of tumor-initiating cells after chemotherapy. Following cisplatin treatment, the
surviving cell population included an increased frequency of clone-initiating cells for both
HepG2 (2.4-fold, p<0.001) and Huh7 cells (2.2-fold, p<0.05) cultured on soft (1kPa) versus
stiff (12kPa) supports (Figure 7B). In addition, there was a non-significant trend towards an
absolute increase in the total number of clone-forming cells from soft supports (data not
shown). To assess the validity of this finding, experiments were repeated using a second,
unrelated chemotherapeutic agent, 5-fluorouracil (5-FU). Consistent with our findings with
cisplatin, following 5-FU chemotherapy there was an increased frequency of clone-initiating
cells from HepG2 (3.6-fold, p<0.001) and Huh7 cells (1.9-fold, p<0.05) cultured on soft
versus stiff supports. There was no difference in the frequency of clone-initiating cells in
untreated HepG2 or Huh7 cells after culture on soft or stiff supports in the absence of
chemotherapy. The paradoxical increase in the clone-initiating capability of chemotherapy-
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treated cells from a low stiffness environment could be explained by selective enrichment
for clone-initiating cells with stem cell characteristics. We therefore performed flow-
cytometric analyses for putative cancer stem cell markers in HCC cells cultured on soft
(1kPa) and stiff (12kPa) supports, both without and following cisplatin treatment (Figure
8A). Culture on soft versus stiff supports was associated with an enrichment for the cell
surface markers CD133 (1.5-fold, p<0.001), c-kit (1.3-fold, p=0.78), CD44 (6.4-fold,
p<0.001) and CXCR4 (2.9-fold, p<0.01). Following cisplatin treatment, there was
statistically significant upregulation of CD44 (1.7-fold, p<0.01), CD133 (1.6-fold, p<0.01)
and c-kit (15.8-fold, p<0.01) for cells maintained on soft but not stiff supports. Additionally,
real-time PCR demonstrated up-regulation of stem cell-associated transcription factors
OCT4 and NANOG in HepG2 cells cultured on soft versus stiff supports, both in untreated
controls (OCT4 2.0-fold increase, p<0.05; NANOG 2.7-fold increase, p<0.05) and following
cisplatin treatment (OCT4 2.0-fold increase, p<0.05; NANOG 3.4-fold increase, p<0.05)
(Figure 8B).
Discussion
In this study we have demonstrated that the stiffness of the sub-cellular matrix profoundly
alters the phenotype and behavior of HCC cells in vitro. Pathophysiological increases in
matrix stiffness – as encountered in fibrotic and cirrhotic livers (19) – promote the
proliferation of HCC cells. Our work defines novel mechanisms linking the physical
properties of the fibrotic liver and the malignant behavior of HCC. Our data is consistent
with in vivo evidence, not only of de novo HCC development and progression against a
background of cirrhosis, but also animal studies showing that the induction of liver fibrosis
is associated with accelerated tumor growth following orthotopic HCC implantation (20,21).
Furthermore, histological examination of human HCC specimens demonstrates a significant
association between the presence of hepatic fibrosis and enhanced tumor cell proliferation
(22). Critically, our findings suggest that a reduction in the stiffness of the cancer cell niche
– as would be encountered by a disseminated tumor cell entering an unaffected secondary
site – would be sufficient to promote reversible cellular quiescence and cancer cell
dormancy.
It has previously been demonstrated that matrix stiffness can regulate proliferation in non-
transformed cells. More recently increased matrix stiffness has been shown to promote
cellular proliferation in glioma cells (23). We have extended these findings to a range of
epithelial malignancies, including HCC (Figure S9). Furthermore, we have shown that β1-
integrin and FAK (the canonical mediator of integrin-related signaling) regulate stiffness-
dependent proliferation in HCC cells. In both fibroblasts and non-transformed mammary
epithelial cells, a critical role for ERK-induced cyclin-D induction has been established in
the stiffness-dependent regulation of cell proliferation (24). In accordance with these
findings we demonstrate both an upregulation of cyclin-D levels and increased mitogenic
signaling through ERK in HCC cells on stiff substrates. Interestingly, reduced ERK
activation has previously been linked to cellular quiescence in a cell line-specific model of
cancer dormancy (25). Additionally, for the first time, we demonstrate a role for matrix
stiffness in modulating the activation of the STAT3 pathway. STAT3 has recently been
identified as a central component in tumor progression and a potential target of cancer
therapy in HCC and other epithelial malignancies (26). The STAT3 pathway is activated in
response to multiple cytokines and growth factors during cancer-associated inflammation
(e.g. interleukin-6, interleukin-10, epidermal growth factor and HGF). Our findings
demonstrate that matrix stiffness has a substantial impact upon the intrinsic and extrinsic
(growth factor-induced) activation of the STAT3 pathway. This indicates an additional role
for biophysical factors in regulating this critical signaling pathway. Interactions between
pathways conveying information from both soluble mediators and the ECM are integrated at
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the level of the cytoskeleton. In this context, the role of cytoskeletal tension has been likened
to a cellular rheostat, acting to dampen or augment the responses of multiple signaling
pathways to growth factor stimulation, thereby blocking or facilitating mitogenic responses.
It has been proposed that the ECM is a critical regulator of cellular dormancy (27); however
the role of matrix stiffness in regulating this process has not been specifically addressed. The
growth, invasion and dissemination of tumor cells are accompanied by dramatic changes in
the mechanical properties (stiffness) of the cancer cell niche. The bone marrow, a common
reservoir site for disseminated tumor cells, provides a microenvironment with stiffness
significantly lower than that encountered in most epithelial tumors (28). Our findings
suggest that a reduction in the stiffness of the cancer cell niche would be sufficient to
promote reversible cellular quiescence (dormancy). Furthermore, increases in environmental
stiffness (as may occur with inflammation, surgery or stromal reaction to tumor) or
alteration in the stiffness-sensing machinery of the cell (as a result of genomic instability)
might facilitate reactivation. Indeed, early work on cancer cell dormancy in animal models
established inflammation and surgical trauma as a mechanism of reactivation of dormant
cells (29,30). More recently, fibrosis-associated collagen-I has been linked to reactivation of
tumor cells in an in vivo model of cancer cell dormancy (31). With respect to the liver,
tumor growth and intrahepatic metastasis have been shown to be enhanced in a fibrotic
environment (20–22).
The precise phenotype of disseminated tumor cells derived from epithelial malignancies
remains poorly defined (32). During tumor dissemination, tumor cells are believed to
acquire mesenchymal properties, enabling them to migrate through and invade surrounding
tissues and enter the bloodstream (33). However, at secondary sites, tumor cells are
primarily detected by their epithelial characteristics and outgrowing metastases recapitulate
the epithelial phenotype of the primary tumor (34). Despite our increasing understanding of
the regulation of epithelial-to-mesenchymal-transition, the reverse process – mesenchymal-
to-epithelial-transition – is largely uncharacterized. We have demonstrated that HCC cells
lose mesenchymal features; including stress-fibers, N-cadherin and vimentin expression, and
up-regulate markers of hepatocyte differentiation when maintained in a soft environment.
This is consistent with previous findings showing that non-transformed mammary epithelial
cells revert to an organized epithelial phenotype in a soft environment (6), and that
hepatocytes retain an epithelial phenotype on soft collagen gels (35). FAK activation has
been implicated in the process of epithelial-to-mesenchymal-transition and responsiveness to
TGFβ (36). It remains unclear whether reduced FAK activation and TGFβ signaling in cells
in a low stiffness environment is a mechanistic link to mesenchymal-to-epithelial-transition.
The high rate of chemotherapy resistance in HCC is a major obstacle in treating patients
with advanced disease. Identifying the mechanism of this resistance has the potential to
reveal new treatment options for this group of patients. We have provided evidence that
increasing ECM stiffness – as encountered by cells within an established tumor (4) –
reduces chemotherapy-induced-apoptosis. However, the clinical utility of systemic
chemotherapy is also limited by the failure of adjuvant/neoadjuvant chemotherapy to target
disseminated tumor cells that give rise to late tumor recurrence and metastases (32,37).
Intriguingly, we have been able to demonstrate an increase in clone-initiating capability
following chemotherapy in cells from a low stiffness environment. This was accompanied
by an increase of cells positive for cancer stem cell markers (CD44, CD133, c-kit, CXCR-4,
OCT4 and NANOG) (38). This provides a potential mechanism for long-term survival and
clone-initiating capability of disseminated tumor cells in a soft environment (e.g. bone
marrow) following chemotherapy. Whether the higher frequency of cells with a cancer stem
cell phenotype is due to positive selection or active induction of cancer stem cell
characteristics needs to be determined.
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In summary, we have provided evidence that the biomechanical composition of the ECM is
a critical regulator of HCC behavior. We suggest that the high stiffness environment
encountered in chronic fibrotic liver disease fosters HCC progression by promoting cellular
proliferation, a mesenchymal phenotype and resistance to chemotherapy. Conversely, a soft
physiological environment (as might be encountered by a disseminated tumor cell) induces
cellular dormancy, a stem cell phenotype and enhanced clonogenic capacity following
chemotherapy. Indeed, we propose that alterations in the stiffness of the cancer cell niche
are responsible for regulating cancer cell proliferation and phenotype throughout the natural
history of HCC. Manipulation of environmental stiffness or interference with the stiffness-
sensing apparatus of HCC cells has the potential to impede both tumor growth and
reactivation of dormant tumor cells, thereby limiting recurrence. In concert with future in
vivo models of HCC, these findings will provide a platform for the future design of therapies
targeting the biomechanical properties of the cancer cell niche.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Changes in matrix stiffness regulate HCC cell morphology and spreading
Huh7 and HepG2 cells were cultured on collagen-I-coated polyacrylamide gels with
“tunable stiffness” (expressed as shear modulus, G’) in the range of 1–12kPa and collagen-I-
coated glass. The stiffness values of the polyacrylamide gel supports used were selected in
order to reflect range of stiffness values encountered in normal and fibrotic livers. Phase-
contrast photomicrographs demonstrate the regulation of cellular morphology by support
stiffness in both (A) Huh7 and (B) HepG2 cells. The surface area (square microns) of (C)
Huh7 and (D) HepG2 cells was calculated by digital image analysis of phase-contrast
images of cells on polyacrylamide gel supports. In each case, values reflect the mean
(±SEM) of measurements from 50 cells in 3 independent experiments (*p<0.05, **p<0.01
and ***p<0.001).
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Figure 2. Changes in matrix stiffness regulate the formation of actin stress fibers and focal
adhesion maturation in HCC cells
Confocal microscopy (×320 magnification) of (A) Huh7 and (B) HepG2 cultured on soft
(1kPa) and stiff (12kPa) collagen-I-coated polyacrylamide supports as indicated. The
photomicrographs displayed are of cells stained for the presence of actin stress fibers
(phalloidin-green), mature focal adhesions (anti-vinculin-red) and nuclear DNA (4’, 6’-
diamidino-2-phenyl-indole dihydrochloride (DAPI-blue). The merged image (right panel)
demonstrates the spatial relationship between actin stress fibers and mature focal adhesions.
Inserts display high magnification images for Huh7 and HepG2 cells cultured on stiff
(12kPa) supports demonstrating the insertion of actin stress fibers into mature focal
adhesions. In each image, the scale bars represent 20 microns.
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Figure 3. Increased matrix stiffness is associated with mesenchymal shift in HCC cells
(A). Western blot from whole cell lysates showing expression of E-cadherin, N-cadherin and
vimentin in Huh7 and HepG2 cells cultured on soft (1kPa) and stiff (12kPa) collagen-I-
coated polyacrylamide gel supports (as indicated). (B). Western blots from whole cell
lysates showing expression of albumin, hepatocyte nuclear factor 4 alpha (HNF4α), α1-
antitrypsin and alpha-fetoprotein (AFP) in Huh7 and HepG2 cells. (C). Western blots from
whole cell lysates from Huh7 cells showing the expression of phospho-Smad2, phospho-
Smad3 and total Smad2/3 following stimulation with transforming growth factor beta
(TGFβ) (5ng/ml). In each western blot equal quantities of protein were loaded and equal
loading confirmed in relation to glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
expression. In each case the western blots shown are representative examples from 3
independent experiments. (D) The line graphs show a schematic representation of
densitometry analysis of phosphorylated Smad2 and Smad3, expressed relative to GAPDH.
Each time-point represents the mean of three independent experiments.
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Figure 4. Increased matrix stiffness promotes HCC cell proliferation
(A) Graphs showing the mean proliferative index (Ki67 positivity) of Huh7 and HepG2 cells
cultured on collagen-I-coated polyacrylamide gel supports across a range of stiffness values
(1–12kPa), as indicated, and collagen-I-coated glass (n=3). (B). Western blots from whole
cell lysates showing expression of cyclin-D1 and cyclin-D3 in Huh7 and HepG2 cells
cultured on soft (1kPa) and stiff (12kPa) supports, as indicated. (C) Western blots from
whole cell lysates showing expression of cyclin-dependent kinase inhibitors, p21cip and
p27kip in Huh7 and HepG2, cultured on soft (1kPa) and stiff (12kPa) supports, as indicated.
In each western blot, equal quantities of protein were loaded and equal loading confirmed in
relation to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression. The western
blots shown are representative examples from 3–6 independent experiments. (D). Graphs
showing the mean proliferative index (Ki67 positivity) of Huh7 (left panel) and HepG2
(right panel) cells cultured on both soft (1kPa) and stiff (12kPa) polyacrylamide supports
coated with collagen-I, collagen-IV, laminin or fibronectin (n=3). In each case, error bars
represent SEM, *p<0.05, **p<0.01 and ***p<0.001.
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Figure 5. Matrix stiffness regulates mitogenic signaling in HCC
(A) Western blots showing basal expression of phosphorylated and total focal adhesion
kinase (FAK), extracellular-regulated kinase ERK, protein kinase B (PKB/Akt) and signal
transducer and activator of transcription 3 (STAT3) in Huh7 and HepG2 cells cultured on
soft (1kPa) and stiff (12kPa) supports, as indicated. (B). Western blots showing cyclin D1
expression in Huh7 and HepG2 cells cultured for 24 hours on soft (1kPa) and stiff (12kPa)
supports in the presence (+) or absence (−) of hepatocyte growth factor (HGF) (10ng/ml).
(C). Western blots showing a time-course analysis for expression of phosphorylated and
total ERK, PKB/ Akt and STAT3 in Huh7 cells cultured on soft (1kPa) and stiff (12kPa)
supports. Whole cell lysates were harvested at baseline and specific timepoints (as indicated)
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following the addition of HGF (10ng/ml) to culture media. In each western blot, equal
quantities of protein were loaded and equal loading confirmed in relation to glyceraldehyde
3-phosphate dehydrogenase (GAPDH) expression. The line graphs (right panel) show a
schematic representation of densitometry analysis of phosphorylated ERK, PKB/ Akt and
STAT3 expressed relative to GAPDH. Each time-point represents the mean of three
independent experiments.
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Figure 6. β1 Integrin and phospho-FAK are expressed in human HCC tumors and regulate the
stiffness-dependent proliferation of human HCC cells in vitro
(A) Low magnification (×50) photomicrographs from a human HCC resection specimen
stained with haematoxylin and eosin (left panel), anti-β1-integrin (middle panel) and anti-
phospho-FAK (right panel). Negative control staining is represented by the indented images
in the top right-hand corner of each image. β1-integrin is expressed in both the HCC tumor
(HCC) and surrounding hepatic parenchyma (P), as indicated. Phospho-FAKTyr397 is
strongly expressed in the HCC tissue relative to the hepatic parenchyma. Scale bars
represent 200 microns. (B) Western blots showing the expression of phospho-FAKTyr397 in
Huh7 and HepG2 cells either left untreated or treated for 24 hours with the focal adhesion
kinase (FAK) inhibitor PF573228 at concentrations of 1µM and 5µM, as indicated. In each
western blot, equal quantities of protein were loaded and equal loading confirmed in relation
to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression. (C) Graphs showing
the mean proliferative index (Ki67 positivity) of Huh7 and HepG2 cells cultured on 12kPa
(stiff) collagen-I-coated polyacrylamide supports. Cells were treated with the anti-β1-
integrin antibody 6S6 (50µg/ml), isotype control IgG1 antibody (50µg/ml), echistatin
(100nm), PF573228 (1µM), PF573228 (5µM), DMSO (vehicle control) or left in media
alone (untreated control) for 24 hours, as indicated (n=3–5). In each case, error bars
represent SEM, *p<0.05, **p<0.01 and ***p<0.001.
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Figure 7. Matrix stiffness regulates apoptosis and clonogenic capacity following chemotherapy
(A) Western blot showing full-length (116kDa) and cleaved poly-ADP-ribose polymerase
(PARP) (89kDa) expression in Huh7 and HepG2 cells following treatment with cisplatin on
soft (1kPa) and stiff (12kPa) supports, as indicated. In each western blot, equal quantities of
protein were loaded and equal loading confirmed in relation to glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) expression. The western blots shown are representative examples
from 3 independent experiments. (B) Colony formation potential of Huh7 and HepG2 cells
following chemotherapy. Huh7 and HepG2 cells were cultured for 48 hours on either soft
(1kPa) or stiff (12kPa) polyacrylamide supports. Cells were then left untreated (left panel) or
treated with cisplatin (middle panel) or 5-fluorouracil (5-FU) (right panel) for 24 hours prior
to media change. After a further 48 hours in culture, the cells were trypsinized and equal
numbers re-plated at clonal density in 12-well plates. Clonogenic capacity was calculated by
direct counting of the resulting colonies. The results are expressed as the percentage colony
formation relative to the number of colonies obtained from 1kPa supports from three
independent experiments.
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Figure 8. Matrix stiffness and chemotherapy regulate stem cell marker expression in HepG2
cells
(A) Quantification by flow cytometric analysis of putative cancer stem cell markers CD133,
c-kit, CD44 and CXCR-4 in HepG2 cells cultured for 5 days on soft (1kPa) or stiff (12kPa)
supports. Cells were either left untreated (black) or treated for 24 hours with cisplatin
(white). Results are representative of three independent experiments. (B) Real-time
quantitative PCR analysis of octamer-4 (OCT4) (left panel) and NANOG (right panel)
expression in HepG2 cells cultured for 5-days on soft (1kPa) or stiff (12kPa) supports. Cells
were either left untreated (black) or treated for 24 hours with cisplatin (white). Expression is
relative to the 18S housekeeping gene. In each case, error bars represent SEM, *p<0.05,
**p<0.01 and ***p<0.001.
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